Silihan lan utang jangka dawa perusahaan Indaptus (INDP)

This chart of current Indaptus Therapeutics (INDP) quotes complements data on the integration of ESG standards into the development of onco-immunological agents and adherence to bioethics. Meanwhile, long-term debt stands at 0.00, as the absence of market sales leaves the company dependent on external investments. The future of the business relies on the success of bacterial vectors in tumor therapy and the protection of intellectual property.

Long-term debt reflects the total liabilities with a maturity exceeding one year. An increase in this metric indicates expanding leverage and the risk of a heightened interest burden. By analyzing the company's long-term debt history, an investor assesses the balance between expansion and financial autonomy. For Indaptus Therapeutics (INDP), borrowed capital can serve as a resource for developing unique oncology drugs, enabling the scaling of innovative immune activation methods.